Antiplatelet Therapy Following TAVI
In the current first patient-level pooled analysis of all available studies on antiplatelet therapy following TAVI, no difference in 30-day NACE rate was observed between ASA only or DAPT. Moreover, ASA was associated with a tendency to a decreased number of life-threatening and major bleedings. Consequently, the additive value of clopidogrel on top of ASA may be questioned and warrants further investigation.
Conclusions
In the current first patient-level pooled analysis of all available studies on antiplatelet therapy following TAVI, no difference in 30-day NACE rate was observed between ASA only or DAPT. Moreover, ASA was associated with a tendency to a decreased number of life-threatening and major bleedings. Consequently, the additive value of clopidogrel on top of ASA may be questioned and warrants further investigation.